Abstract Gene rearrangements involving the Ewing sarcoma breakpoint region 1 (EWSR1) gene are seen in a broad range of sarcomas and some nonmesenchymal neoplasms. Ewing sarcoma is molecularly defined by a fusion of the EWSR1 gene (or rarely the related FUS gene) to a member of the E26 transformation-specific (ETS) family of transcription factors, frequently the EWSR1-FLI1 fusion. More recently, EWSR1 gene fusion to non-ETS family members, including the nuclear factor of activated T cells, cytoplasmic, calcineurin-dependent 2 (NFATC2) gene, has been reported in a histological variant of Ewing sarcoma. Here, we report a malignant round cell tumor of bone with an EWSR1-NFATC2 fusion gene. This report builds upon the unusual morphological and clinical presentation of bone neoplasms containing an EWSR1-NFATC2 fusion gene.
Introduction
Ewing sarcoma is small-round-cell, high-grade tumor that primarily affects the bone and soft tissue of young adults and children. Ewing sarcoma is molecularly defined by translocations resulting in the fusion of the EWSR1 gene, located at 22q12 (or rarely the FUS gene, located at 16p11), and a gene of the E26 transformation-specific (ETS) family of transcription factors [1] . In 85 to 90 % of cases, the translocation is t(11;22)(q24;q12) resulting in EWSR1-FLI1 fusion gene [2, 3] . The ERG gene, located at 21q22, is the fusion partner to EWSR1 in about 5 to 10 % of cases of Ewing sarcoma [4] . Other fusion partners described in the ETS family members include ETV1 (7p22) [5] , ETV4 (17q12) [6] , and FEV (2q33) genes [7] . These translocations result in the fusion of the N-terminal transactivation domain of EWSR1 with the C-terminal DNA-binding domain of the ETS family member generating a potent and oncogenic transcription factor [8] . EWSR1 gene fusions are presumed to be the important oncogenic event in Ewing sarcoma [9] . The EWSR1-FLI1 fusion promotes numerous oncogenic properties, including cell proliferation, transformation, in vivo tumor growth, and chemoresistance in experimental models, and is considered a therapeutic target [9] [10] [11] [12] [13] .
More recently, rare cases of Ewing sarcoma-like tumors with fusions between EWSR1 and non-ETS family members have been described. These cases showed fusion partner genes, PATZ1 [14] and SP3 [15] , encoding proteins in the zinc-finger family; SMARCA5 [16] , encoding a chromatin-remodeling protein; and NFATC2 [17] , encoding a member of the NFAT-transcription family. The rearrangement of the EWSR1 gene is not specific to the Ewing sarcoma family of tumors. Distinct translocations involving the EWSR1 gene and non-ETS transcription family members are seen in several other mesenchymal neoplasms, including desmoplastic small-round-cell tumor [18] , clear cell sarcoma of soft tissue [19] , angiomatoid fibrous histiocytoma [20] , extraskeletal myxoid chondrosarcoma [21] , myxoid liposarcoma [22] , primary pulmonary myxoid sarcoma [23] , myoepithelial tumors [24] [25] [26] , and hemangioma of bone [27] . In addition to mesenchymal tumors, EWSR1 gene fusions have also been described in hyalinizing clear cell carcinoma of salivary gland [28] , and in rare cases of mesothelioma [29] and mucoepidermoid carcinoma of salivary gland [30] .
Here, we report an aggressive tumor of the bone with focal small-round-cell features in a young male adult characterized by the amplification of the EWSR1-NFATC2 fusion gene. Bone tumors characterized as Ewing sarcoma variants [17, 31] and myoepithelioma-like sarcoma [32] have been recently described to contain the amplified EWSR1-NFATC2 gene fusion. The case described in this report builds upon prior cases and expands the morphological spectrum of tumors described to contain amplification of this gene fusion.
Case report
A previously healthy 30-year-old man presented with constant burning and stabbing pain of the left thigh over a 6-week period. He reported no history of trauma or infection. A mixed lytic and blastic lesion involving the mid-left femoral diaphysis was identified on plain radiograph. The lesion had a benignappearing surrounding sclerosis and periosteal reaction. No soft tissue extension was seen on CT. Curettage with bone graft was performed, and after correlation with the radiographic findings, a diagnosis of aggressive osteoblastoma was rendered on histological examination.
Two and half years later, the patient returned with complaint of persistent left leg pain and no other constitutional symptoms. There was a worsening appearance of the mid-left femur lesion. An aggressive, ill-defined, lytic-type process, measuring 8.3 cm in length and involving the cortex with thick periosteal reaction and a calcified matrix was seen on plain radiographs (Fig. 1) . Curettage biopsy and subsequent surgical resection were performed. The tumor extended into the surrounding connective tissue and skeletal muscle. In conjunction with outside expert consultation, the recurrent lesion was initially diagnosed as an osteosarcoma with small-cell features arising from an aggressive osteoblastoma. Due to positive surgical margins, the patient underwent 3 months of etoposide and ifosfamide chemotherapy, with complications of renal failure and sepsis. Chemotherapy was discontinued, and he was followed by close surveillance. Four months after his resection, his radiological scans revealed intact hardware with no evidence of tumor recurrence or metastasis. Two more months later, the patient was lost on follow-up.
Methods
The biopsy and curettage specimens were received fresh, fixed in 10 % buffered formalin, and processed for routine histological analyses. Histological and immunohistochemical analyses were done on 5-μm-thick sections and using a Leica processor (Leica Microsystems, Buffalo Grove, IL). Antibodies used were against AE1/3 (1:400; Leica Microsystems), Fluorescence in situ hybridization (FISH) for rearrangement of the EWSR1 locus was performed using an EWSR1 dual-color break-apart probe (22q12) (Vysis/Abbot Laboratories, Downers Grove, IL). FISH analysis of the EWSR1-FLI1 fusion was performed using a FLI1/EWSR1 translocation dual-fusion probe (Cytocell, Cambridge, MA). These two FISH assays were performed according to manufacturers' instructions. The EWSR1-NFATC2 fusion was investigated by a dual-color FISH assay with Spectrum Green-labeled BAC clones RP11-367E7 and RP11-480L23 corresponding to the EWSR1-5′ region and Spectrum Red-labeled BAC clones RP11-2L23 and RP11-73P15 corresponding to the NFATC2-3′ region (Empire Genomics, Buffalo, NY). The FISH assay was performed on tumor sections as described previously [33] .
An RT-PCR assay for the EWSR1-NFATC2 fusion transcript was performed with an EWSR1 exon 8 forward primer (TGGGTGTTTATGGGCAGGAGTC) and an NFATC2 exon 5 reverse primer (GCTCAATGTCGGCGTTTCTAAG) to amplify a 573 base pair product. As a control assay, the wild-type FOXO1 transcript was assayed by RT-PCR with an FOXO1 exon 1 forward primer (GCAGATCTACGAGT GGATGG) and an FOXO1 exon 2 reverse primer (AACTGT GATCCAGGGCTGTC) to amplify a 323 base pair product. The RT-PCR was performed with the SuperScript III One-
Step RT-PCR System with Platinum Taq DNA Polymerase (Life Technologies, Carlsbad, CA).
Results
The original curettage revealed osteoblast-rimmed irregular bony trabecula with loose fibrovascular intertrabecular spaces (Fig. 2a, b ). There were foci of atypical cells with pale to clear cytoplasm, oval nuclei, and nucleoli (Fig. 2c) . These cells were vimentin positive and had unusual "dot-like" AE1-3 staining (Fig. 2d) ; all other cytokertains (Cam5.2, CK7, CK19, CK20) were negative. Other negative stains included p63, CD34, SMA, myogenin, desmin, EMA, MSA, S100, Melan A, HMB45, synaptophysin, CD117, CD99, Oct3/4, LCA, CD3, CD15, CD20, CD30, and CD68. Rare larger hyperchromatic nuclei were identified. No infiltration into adjacent tissue was identified. After consideration of morphological, immunohistochemical, and benign radiologic findings, the diagnosis of an aggressive osteoblastoma was rendered.
Two and half years later, the subsequent biopsy and resection showed areas resembling the prior biopsy with similar vascularity, bony trabecula, and osteoid-rimmed osteoblasts (Fig. 3a, b ). There were also diffuse sheets and clusters of atypical cells with eosinophilic cytoplasm, irregular nuclear contours, and prominent nucleoli (Fig. 3c, d ). Within the loose fibrovascular stroma were foci of smaller cells with scant cytoplasm, oval nuclei, and occasional small nucleoli (Fig. 3e, f ). There were large areas of necrosis with variable mitotic activity (up to 8 per high power field), consistent with 2, AE1-3 ), neuronal markers (S100, neurofilament), LCA, CD56, CD68, WT1, synaptophysin, and EMA. In conjunction with outside expert consultation, the recurrent lesion was initially diagnosed as an Given the foci of small blue cells with CD99 immunoreactivity in the recurrent specimen, an interphase FISH assay using an EWSR1 dual-color break-apart probe was performed on paraffin sections of nondecalcified tissue. The FISH assay showed numerous copies (>15/nucleus) of the proximal region flanking the EWSR1 gene while the distal region remained normal in copy number but separate from centromeric region (Fig. 4a) . These results suggested an amplification of the proximal region flanking EWSR1 and potential break apart in EWSR1. To look for rearrangement partner, interphase FISH using a dual-fusion EWSR1-FLI1 probe set was performed and did not reveal an EWSR1-FLI1 fusion. Based on the previous finding of bone tumors with EWSR1-NFATC2 amplification, FISH using an EWSR1-NFATC2 fusion probe set was performed and revealed numerous copies of the EWSR1-NFATC2 fusion (>15/nucleus; Fig. 4b, c) . The amplification pattern was in concordance with the the proximal EWSR1-5′ probe hybridization in the EWSR1 break-apart probe assay. To further characterize the fusion, RT-PCR was performed for the EWSR1-NFATC2 fusion transcript and detected the predicted 573 base pair fragment (Fig. 4d) . Sequence analysis of the PCR product showed a junction between the 3′ end of EWSR1 exon 8 of and the 5′ end of NFATC2 exon 3, forming an in-frame transcript (Fig. 4e) . Based on these findings, the break-apart and fusion FISH assays were retrospectively performed on the original curettage material and revealed similar results.
Discussion
The discovery of the EWSR1-NFATC2 gene fusion in both the initial and follow-up specimens best supports the characterization of this tumor as an Ewing sarcoma variant. In retrospect, the lack of CD99 and neuroendocrine marker immunoreactivity along with the misinterpretation of the florid osteoblastic proliferation as part of the tumor, rather than a reaction to the tumor, led to a misclassification of the original lesion as an aggressive osteoblastoma.
Two years after conservative treatment, the patient developed a local malignant recurrence. The EWSR1-NFATC2 amplification was detected in both the initial presentation and malignant recurrence, and the copy number did not increase with disease progression. The presence of EWSR1-NFATC2 fusion, focal small-round-cell morphology, and CD99 immunopositivity in the reoccurrence favor an Ewing-like sarcoma. Two different neoplastic cell populations were seen in the recurrent tumor. There were foci of small cells with (Fig. 3e, f) that resemble typical Ewing sarcoma. There were also diffuse sheets of larger cells with eosinophilic cytoplasm, irregular nuclear contours, and prominent nucleoli (Fig. 3c, d ) that are more consistent with "atypical" Ewing sarcoma [34] . The clinical presentation of only local recurrence without metastasis in more than 2 years after conservative curettage treatment is less common in typical Ewing sarcoma [35] .
Small-cell osteosarcoma is a rare morphological variant of osteosarcoma that morphologically resembles Ewing sarcoma. Although malignant osteoid formation remains the hallmark of osteosarcoma, Ewing sarcoma can have osteoid deposits, most likely reactive osteoid formation secondary to bone destruction [35] . Like Ewing sarcoma, small-cell osteosarcoma can also show positive CD99 membrane staining [36] , although additional FLI1 immunoreactivity favors Ewing sarcoma [37] . Moreover, EWSR1 gene fusions, such as EWSR1-CREB3L1 [38] , have been described in small-cell osteosarcomas [39] . These findings have been challenged by some that believe these reported tumors should be classified in the Ewing sarcoma family regardless of whether they produce osteoid, implying that it is possible that some of the tumors classified as small-cell osteosarcomas actually are Ewing sarcoma with divergent differentiation [40] . Distinguishing between these two entities is not a trivial matter given the differences in therapeutic approach and response to chemoradiation therapy [41, 42] .
Molecular detection of tumor-specific translocations has been widely used as a reliable diagnostic tool in soft tissue sarcomas and is beginning to be more commonly applied to bone tumors [43] . However, the diagnostic implication of any molecular finding needs to be interpreted with morphological, radiological, and clinical correlation as translocations with the same gene fusion are increasingly being discovered in different tumors with distinct morphology and clinical presentation. For example, EWSR1-ATF1 is present in clear cell sarcoma of soft part and angiomatoid histiocytoma, two morphologically and clinically unrelated soft tissue tumors [20] . The amplification of the EWSR1-NFATC2 fusion gene present in our case has been described in a series of Ewing sarcoma-like tumors [17] as well as a myoepithelioma-like sarcoma of the bone [32] . Our case shares similarities with Ewing sarcoma-like tumors previously described [17, 31] , being present in a patient older than 18 years of age, showing CD99 positivity (only on the reoccurrence) and unusual morphology with atypical cells and occasional prominent nucleoli (primarily in the reoccurrence). The diffuse dot-like cytokeratin immunoreactivity has previously been described in Ewing sarcoma [34] .
In summary, we reported an additional case of malignant bone sarcoma in a young male adult containing the recently reported EWSR1-NFATc2 fusion gene. Similar to the few prior reported cases, the EWSR1-NFATc2 fusion gene was amplified in the current case [17, 31] . Although the previously reported cases were mostly regarded as Ewing sarcoma variant based on the morphological features and finding of the EWSR1 translocation, little is known about the biology of these rare tumors. Before being lost to follow-up, the current case was followed for almost 3 years. The unusual adjacent reactive osteoblastic proliferation, atypical morphology, and only local recurrence 2.5 years following conservative curettage treatment suggest a very unusual variant of Ewing sarcoma family that has not been well described.
